Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Financing Activities: 2015-2020

Historic Cash from Financing Activities for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $660,771.

  • Outlook Therapeutics' Cash from Financing Activities rose 1059.78% to $660,771 in Q3 2020 from the same period last year, while for Sep 2020 it was $37.2 million, marking a year-over-year decrease of 4.65%. This contributed to the annual value of $60.3 million for FY2024, which is 23.20% up from last year.
  • Per Outlook Therapeutics' latest filing, its Cash from Financing Activities stood at $660,771 for Q3 2020, which was down 97.47% from $26.2 million recorded in Q2 2020.
  • In the past 5 years, Outlook Therapeutics' Cash from Financing Activities ranged from a high of $27.2 million in Q2 2016 and a low of -$504,763 during Q3 2016.
  • In the last 3 years, Outlook Therapeutics' Cash from Financing Activities had a median value of $6.2 million in 2019 and averaged $8.2 million.
  • As far as peak fluctuations go, Outlook Therapeutics' Cash from Financing Activities slumped by 114.13% in 2018, and later skyrocketed by 3,426.07% in 2019.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Cash from Financing Activities stood at $5.7 million in 2016, then surged by 256.82% to $20.4 million in 2017, then crashed by 58.19% to $8.5 million in 2018, then plummeted by 100.10% to -$8,293 in 2019, then spiked by 1,059.78% to $660,771 in 2020.
  • Its Cash from Financing Activities was $660,771 in Q3 2020, compared to $26.2 million in Q2 2020 and $10.4 million in Q1 2020.